VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics. According to the press release, these innovations could address critical limitations in current cancer treatments, such as off-target toxicity and limited efficacy against heterogeneous tumors.
The expanded patent portfolio is a key milestone for VERAXA as it advances its pipeline toward clinical development. The company's BiTAC (Bispecific T-cell engager with Anti-tumor Cytotoxicity) platform represents a novel approach that requires the presence of two tumor-associated antigens to activate T cells, potentially reducing damage to healthy tissues. This dual-targeting mechanism is complemented by the company's proprietary technologies in antibody-drug conjugates (ADCs), which deliver cytotoxic payloads directly to cancer cells.
VERAXA's intellectual property strategy aims to create a robust barrier to entry for competitors, ensuring that its technological innovations remain exclusive for years to come. The portfolio now includes patents in key markets such as the United States, Europe, and Japan, covering not only the BiTAC platform but also the underlying conjugation and linker technologies that are critical for manufacturing and therapeutic performance.
These developments are significant for the biotech sector, as they signal VERAXA's commitment to building a comprehensive IP moat around its pipeline. Investors and industry observers will be watching how the company leverages these protections to secure partnerships or advance its own clinical trials. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For more information on VERAXA Biotech AG, visit the company's newsroom at http://ibn.fm/VRXA. To view the full press release, visit https://ibn.fm/BqhFS.
